-
2022-502531-18-00
5
2024-01-18
Obesity
-
2022-502540-12-00
5
2023-11-09
Refractory Status Epilepticus (RSE)
-
2022-502077-42-00
10
2023-09-14
generalised anxiety disorder
-
2022-502196-31-00
10
2023-08-21
Advanced or Recurrent Endometrial Cancer
-
2022-502483-21-00
4
2023-07-28
Insomnia disorder
-
2022-503022-13-00
5
2023-06-08
Hypertriglyceridemia, Cardiovascular Diseases, Atherosclerosis
-
2022-501063-41-00
5
2023-04-20
Chronic Obstructive Pulmonary Disease (COPD)
-
2023-503793-20-00
5
2023-01-18
Prevention of ischemic stroke in patients post acute non-cardioembolic
-
2022-500332-11-00
4
2022-11-25
systemic sclerosis
-
2023-503794-38-00
5
2022-11-24
Prevention of stroke or systemic embolism in atrial fibrillation
-
2024-517444-64-00
9
2022-05-30
Chronic Myelomonocytic Leukemia
-
2023-503571-19-00
5
2022-01-20
Chronic Obstructive Pulmonary Disease (COPD)
-
2024-510782-42-00
5
2021-10-15
Platinum-resistant or refractory, high-grade serous ovarian cancer wit
-
2024-510744-31-00
5
2021-10-06
Giant cell arteritis (GCA)
-
2023-506918-45-00
5
2021-05-17
Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
-
2023-506919-18-00
5
2021-05-17
Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
-
2024-512837-34-00
5
2020-10-14
Episodic and Chronic Migraine
-
2023-507669-24-00
5
2019-11-05
Chronic lymphocytic leukemia
-
2023-503673-38-00
5
2019-05-24
Adults at high risk of cardiovascular events without prior MI or strok
-
2022-502747-35-00
5
2019-02-18
Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ova
-
2022-502938-30-00
5
2018-12-10
Moderate and Severe Atopic Dermatitis
-
2023-508010-42-00
5
2016-09-14
Homologous recombination deficiency advanced ovarian cancer
-
2023-506487-13-00
5
Hormone receptor-positive, her2-negative advanced/metastatic breast ca
-
2024-512255-20-00
4
Clinical development and proof of principle testing of new regenerativ